BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 32534369)

  • 1. Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma.
    Medina MT; Moncada SS
    J Neurol Sci; 2020 Aug; 415():116972. PubMed ID: 32534369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
    Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
    Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
    Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Miller MC; Abraham GM; Obley AJ; Forciea MA; Jokela JA; Humphrey LL;
    Ann Intern Med; 2020 Jul; 173(2):W48-W51. PubMed ID: 32551892
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
    Funck-Brentano C; Salem JE; Nguyen LS; Drici MD; Roden DM
    Arch Cardiovasc Dis; 2020 May; 113(5):367-368. PubMed ID: 32331979
    [No Abstract]   [Full Text] [Related]  

  • 5. The continued dilemma about the usage of hydroxychloroquine: Respite is in randomized control trials.
    Malviya A
    Int J Infect Dis; 2020 Oct; 99():310-311. PubMed ID: 32738490
    [No Abstract]   [Full Text] [Related]  

  • 6. Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
    Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Humphrey LL
    Ann Intern Med; 2020 Sep; 173(5):W88-W89. PubMed ID: 32730105
    [No Abstract]   [Full Text] [Related]  

  • 7. Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.
    Decloedt EH; Reuter H; Allwood B; Parker A; Koegelenberg CFN; Blockman M; Taljaard J
    S Afr Med J; 2020 Apr; 110(5):12903. PubMed ID: 32657706
    [No Abstract]   [Full Text] [Related]  

  • 8. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.
    Hernandez AV; Roman YM; Pasupuleti V; Barboza JJ; White CM
    Ann Intern Med; 2020 Aug; 173(4):287-296. PubMed ID: 32459529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
    Biguetti C; Marrelli MT; Brotto M
    Rev Saude Publica; 2020; 54():68. PubMed ID: 32638884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
    Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Meo SA; Klonoff DC; Akram J
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4539-4547. PubMed ID: 32373993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic].
    Zaidel EJ; Wyss Quintana FS; Sosa Liprandi Á; Mendoza I; Márquez MF; Nuñez E; Barbosa M; Baranchuk A
    Medicina (B Aires); 2020; 80(3):271-274. PubMed ID: 32442941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.
    Jankelson L; Karam G; Becker ML; Chinitz LA; Tsai MC
    Heart Rhythm; 2020 Sep; 17(9):1472-1479. PubMed ID: 32438018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).
    Gao J; Hu S
    Biosci Trends; 2020 May; 14(2):156-158. PubMed ID: 32281583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ICMR bulletin on targeted hydroxychloroquine prophylaxis for Covid-19: Need to interpret with caution.
    D'Cruz M
    Indian J Med Ethics; 2020; V(2):100-102. PubMed ID: 32393448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
    Hsia BC; Greige N; Quiroz JA; Khokhar AS; Daily J; Di Biase L; Ferrick KJ; Fisher JD; Krumerman A
    J Interv Card Electrophysiol; 2020 Nov; 59(2):337-345. PubMed ID: 32654098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
    Gautret P; Lagier JC; Parola P; Hoang VT; Meddeb L; Mailhe M; Doudier B; Courjon J; Giordanengo V; Vieira VE; Tissot Dupont H; Honoré S; Colson P; Chabrière E; La Scola B; Rolain JM; Brouqui P; Raoult D
    Int J Antimicrob Agents; 2020 Jul; 56(1):105949. PubMed ID: 32205204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
    Ramireddy A; Chugh H; Reinier K; Ebinger J; Park E; Thompson M; Cingolani E; Cheng S; Marban E; Albert CM; Chugh SS
    J Am Heart Assoc; 2020 Jun; 9(12):e017144. PubMed ID: 32463348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.